Table 1 Skin reactions to imatinib
(A) | Age (years)/gender | Localization of metastases | Skin reaction | CTC grading | Onset of reaction (days after first application of imatinib) | Dose adjustment |
|---|---|---|---|---|---|---|
Patient 1 | 71/m | Liver, spleen, subcutaneous | None | 0 | None | None |
Patient 2 | 51/f | Lung, subcutaneous | Generalised macular and urticarial eruption | 3 | 10 | 50% reduction |
Patient 3 | 41/f | Lymph nodes, subcutaneous | Generalized macular and urticarial eruption | 3 | 5 | 50% reduction, corticosteroids |
Patient 4 | 69/f | Skin | Macular rash of the face | 2 | 7 | None |
(B) | Author, year of publication | Imatinib dose (mg day−1) | Number of patients treated |  | Mild or moderate cutaneous reactions (CTC grade 1–2) | Severe cutaneous reactions (CTC grade 3–4) |
CML | 400 | 532 | Â | 155 (29.1%) | 16 (3.0%) | |
CML | 400–600 | 235 |  | 49 (20.8%) | 3 (1.3%) | |
CML | 400–600 | 260 |  | 48 (18.5%) | 11 (4.2%) | |
GIST | van Oosterom et al (2001) | 400–1000 | 40 |  | 17 (42.5%) | 5 (12.5%) |
GIST | 400–600 | 147 |  | 41 (27.9%) | 4 (2.7%) |
